Open Bar: Vitamin K and the Newborn

Question: How do you address parents who refuse treatment for newborns?

Answer. Parental refusal of vitamin K and erythromycin prophylaxis presents a recurring challenge for health care personnel involved in newborn care. In New York, this issue sits at the intersection of regulatory requirements, parental decision-making authority and broader malpractice principles. While the State mandates administration of these treatments, guidance from regulators and existing case law reflects a more nuanced reality.

New York’s Regulatory Framework

New York regulations impose an affirmative duty on healthcare personnel attending to a newborn to administer both vitamin K and erythromycin prophylaxis. An attending physician, licensed midwife, licensed nurse or other authorized provider must ensure administration of a single intramuscular dose of vitamin K within six hours of birth¹. Similarly, the law requires administration of an agent, such as erythromycin ophthalmic ointment, to prevent purulent conjunctivitis of the newborn². Unlike vaccination laws, these provisions place the obligation directly on healthcare personnel as part of standard newborn care.

Parental Refusal in Practice

Despite the regulatory mandate, parental refusal of vitamin K and erythromycin prophylaxis does occur. The New York State Department of Health (“NYSDOH”) has acknowledged this reality and issued guidance addressing how health care personnel should respond. NYSDOH instructs that when parents object, health care personnel should educate parents regarding the purpose, safety and necessity of the treatments, including the risks associated with declining them, and document both the education provided and any refusal³.

NYSDOH has also clarified that refusal of these preventive interventions, standing alone, does not constitute child maltreatment and is generally not reportable to the Child Protective Services absent additional risk factors⁴.

Legal Considerations

The legal landscape surrounding refusal is shaped by both public health regulations and malpractice law principles. New York’s informed consent statute governs claims based on failure to disclose risks, benefits and alternatives associated with certain treatments involving an invasion of bodily integrity⁵. While there are no reported New York cases specifically addressing informed consent for vitamin K or erythromycin prophylaxis, courts have recognized in other contexts that injections may implicate informed consent principles, particularly where a treatment involves a physical invasion of the body.

At the same time, New York courts have emphasized that informed consent is limited in scope and does not apply to all aspects of routine medical care⁶. Vitamin K and erythromycin prophylaxis are generally understood as standard neonatal interventions⁷.

This creates a legal framework in which both concepts coexist: New York imposes a duty to administer the treatments, while malpractice law recognizes that certain medical interventions may be evaluated through the lens of disclosure and patient decision-making.

Documentation and Risk Considerations

NYSDOH guidance places particular emphasis on documentation. When parents refuse vitamin K or erythromycin prophylaxis, healthcare personnel are instructed to document the education provided, the information discussed regarding risks and benefits and the parents’ decision to decline the treatment⁸. Situations involving refusal may raise questions about documentation, communication with parents, and how clinical encounters are reflected in the medical record.

Conclusion

Parental refusal of vitamin K and erythromycin prophylaxis highlights the intersection of multiple legal and clinical considerations. New York regulations treat these interventions as mandatory components of newborn care, while also acknowledging that refusal occurs and focuses on education and documentation in those situations. At the same time, broader malpractice principles recognize that certain medical interventions may implicate issues of disclosure and consent.

As a result, healthcare personnel navigating these situations operate within a framework where regulatory requirements, parental decision-making and liability considerations all intersect, and where the available authority reflects each of those competing considerations. Therefore, healthcare personnel should work closely with healthcare and business counsel to develop a clear, consistent approach for addressing vitamin K and erythromycin prophylaxis treatments.

MLMIC policyholders can reach out to our healthcare attorneys for questions about the administration of Vitamin K in an infant, informed consent or any other healthcare law inquiries by calling (877) 426-9555 Monday-Friday, 8 a.m.-6 p.m. or by email here.

Our 24/7 hotline is also available for urgent matters after hours at (877) 426-9555 or by emailing hotline@tmglawny.com.

Follow us on Facebook, LinkedIn, Instagram or Twitter to stay in the loop about the medical professional liability industry.

If you are not already a MLMIC insured, learn more about us here.

This document is for general purposes only and should not be construed as medical, dental or legal advice. This document is not comprehensive and does not cover all possible factual circumstances. Because the facts applicable to your situation may vary, or the laws applicable in your jurisdiction may differ, please contact your attorney or other professional advisors for any questions related to legal, medical, dental or professional obligations, the applicable state or federal laws or other professional questions.

1. 10 NYCRR § 12.3 ↩︎
2. 10 NYCRR § 12.2 ↩︎
3. https://www.health.ny.gov/professionals/hospital_administrator/letters/2025/docs/dal_25-04.pdf ↩︎
4. Id. ↩︎
5. Public Health Law § 2805-d ↩︎
6. Lindsay-Thompson v Montefiore Med. Ctr., 147 AD3d 638 [1st Dept 2017] ↩︎
7. https://publications.aap.org/first1000days/pages/delivery-and-care?autologincheck=redirected ↩︎
8. https://www.health.ny.gov/professionals/hospital_administrator/letters/2025/docs/dal_25-04.pdf ↩︎